Pharma

Pharma articles offer sharp opinion and analysis of Big Pharma, exposing industry practices, regulatory capture, profit motives, and their impacts on economics, public policy, public health, social life, trust in medicine, and individual liberty.

We cover critical topics like Pfizer trial irregularities, vaccinology “big lies”, COVID vaccine cardiac risks, industry influence on regulation, ACIP decisions, medical journal failures, vaccine safety debates, and calls for accountability, transparency, and evidence-based reform.

All articles from Brownstone Institute are translated into multiple languages to reach global readers, foster international dialogue on pharmaceutical accountability, and challenge centralized industry power.

Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America

Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America

SHARE | PRINT | EMAIL

Following Trump’s proposal, HCQ came under an unwarranted full-scale attack from federal officials, the press, “fact-checkers,” and university professors. Many of the attacks contained falsehoods about HCQ’s pharmacology and safety or Trump’s endeavor to make HCQ available to eligible patients.

Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America Read Journal Article

Join the Brownstone Community
Get our FREE Journal Newsletter